The EU needs a “robust signaling system” that can accurately detect and mitigate vulnerabilities in the supply chains for “critical” medicines using a risk-based approach with harmonized definitions and quality standards, says a new report from the European Commission’s Health Emergency Preparedness and Response Authority (HERA).
Marketing authorization holders (MAHs) see manufacturing and logistical issues as the main reasons for supply chain discontinuities, notably the complexity...